Skip to content
Buy This GLP
← Research
Evidence

Endoscopic Sleeve Gastroplasty vs. GLP-1s: What Studies Found

Two studies found more weight loss with the procedure at six months. Both had uncertain differences at 12 months.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Total body weight lost in one cohort6 months12 monthsprocedure 12.72%11.92%tablet 8.67%10.91%Six-month difference P = 0.0001. Twelve-month P = 0.41.

Endoscopic sleeve gastroplasty, or ESG, reduces stomach capacity by placing stitches through an endoscope passed through the mouth. Research on how quickly weight changes on a GLP-1 provides context for reading the follow-up periods. Two studies found more weight loss with ESG at six months, but used different medications and could not establish which treatment performs better over the long term.[1][2][3]

What the direct comparisons found

In a retrospective cohort of 150 adults, average total body weight loss at six months was 12.72% with ESG and 8.67% with oral semaglutide 14 mg. At 12 months, it was 11.92% and 10.91%, respectively (P = 0.41). During follow-up, 18 people stopped semaglutide and five ESG patients started it. The later comparison did not establish that outcomes were equivalent.[1]

In a separate randomized trial of 43 adults, weight loss was greater with ESG than liraglutide at three and six months. At 12 months the study found no statistically clear difference. Neither comparison evaluated an injectable semaglutide or tirzepatide regimen as the initial alternative to ESG.[1][2]

Results after an earlier sleeve gastrectomy

A retrospective study of treatment for weight regain after bariatric surgery included 22 people who had revisional ESG and 68 who received medication. At 12 months, average total weight loss was 13.4% after the procedure and 9.2% in the medication group (P = 0.07). The tirzepatide subgroup averaged 13.2%, but the study cannot establish equivalent effects.[4]

What the five-year cost model assumed

A 2024 U.S. health care model for adults with class II obesity used 2022 dollars and assumed an annual semaglutide price of $13,618. Under those assumptions, ESG cost $33,583 less over five years and produced 0.06 more modeled quality-adjusted life-years. The model estimated that different drug prices could change the comparison. Those are modeled health care costs and outcomes, rather than measured patient bills or trial results.[3]

Frequently asked

Does endoscopic sleeve gastroplasty lead to more weight loss than a GLP-1?
Two head-to-head studies found more weight loss with gastroplasty at six months than with the medications they tested. At 12 months, neither found a statistically clear difference, and neither established equivalence.
Does gastroplasty cost less than semaglutide?
A 2024 U.S. model estimated lower total health care costs for the procedure over five years at its assumed semaglutide price. It did not estimate what an individual patient will pay.

Sources

  1. [1] Jagtap N, Golchha A, Katrevula A, Asif S, Rughwani H, Koduri KK, et al. (2026). Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study Endoscopy. PMID 42259388
  2. [2] Nigro S, Vinciguerra F, Guccione F, Alibrandi A, Filannino R, Navarra G (2025). Comparative Efficacy of Endoscopic Sleeve Gastroplasty (Esg) Versus Liraglutide in Weight Loss and Remission Of Obesity-Related Comorbidities: Twelve Months Follow-Up Results Obesity Surgery. PMID 40779281
  3. [3] Haseeb M, Chhatwal J, Xiao J, Jirapinyo P, Thompson CC (2024). Semaglutide vs Endoscopic Sleeve Gastroplasty for Weight Loss JAMA Network Open. PMID 38607627
  4. [4] Bahdi F, Shah S, Dahoud F, Farooq M, Kozan P, Kim S, et al. (2025). Revisional endoscopic sleeve gastroplasty versus semaglutide and tirzepatide for weight recidivism after sleeve gastrectomy Clinical Obesity. PMID 39909715

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence